Bone and immune system are functionally interconnected. Immune and bone cells derive from same progenitors in the bone marrow, they share a common microenvironment and are being infl uenced by similar mediators. The evidence on increased bone resorption associated with inappropriate activation of T cells such as during infl ammation, is well established. However, the molecular mechanisms beyond this clinical observation have begun to be intensively studied with the advancement of osteoimmunology. Now days, we have fi rm evidence on the infl uence of numerous proinfl ammatory cytokines on bone cells, with the majority of data focused on osteoclasts, the bone resorbing cells. It has been shown that some proinfl ammatory cytokines could possess osteoclastogenic and/or anti-osteoclastogenic properties and can target osteoclasts directly or via receptor activator of nuclear factor κB (RANK)/RANK ligand(RANKL)/osteoprotegerin (OPG) system. Several studies have reported opposing data regarding (anti)osteoclastogenic properties of these cytokines. Therefore, the fi rst part of this review is summarizing current evidence on the infl uence of pro-infl ammatory cytokines on osteoclasts and thus on bone resorption. In the second part, the evidence on the role of pro-infl ammatory cytokines in osteoporosis and osteoarthritis is reviewed to show that unravelling the mechanisms beyond such complex bone diseases, is almost impossible without considering skeletal and immune systems as an indivisible integrated system.
Introduction
It is now well established that bone and immune cells are functionally connected. Diverse interactions between bone and immune cells occur within the bone microenvironment. Bone marrow serves as a site for priming naive T cells, recruitment of eff ector T cells and their proliferation (1, 2) . Bone and immune cells share the same progenitors residing in bone marrow and are being aff ected by the same cytokines, infl uencing hematopoiesis, local immune responses and bone cells as well. In addition, diff erent immune cells such as macrophages, B lymphocytes, mast cells, natural killer cells (NK), etc. have been shown to infl uence bone cells as well. However, the most powerful players in this regulation are activated T cells. Following successful antigen-specifi c activation in secondary lymphoid tissues, T cells begin to produce numerous pro-infl ammatory cytokines such as interleukin (IL)-2, -4, -5, -6 and -8, tumor necrosis factor-α (TNF-α), transforming growth factor-β (TGF-β), granulocyte-macrophage colony stimulating factor (GM-CSF), interferon γ (IFN-γ), etc. (3). These pro-infl ammatory cytokines are soluble mediators with pleiotropic eff ects on diff erent types of cells. Interestingly, they aff ect bone cells within a particular bone microenvironment. The pro-infl ammatory cytokines can be classifi ed either based on the primary source of their production, i.e. the type of immune cell or their specifi c targets in bone, i.e. bone cells and thus the process they Zupan J. et al. Osteoimmunology and pro-infl ammatory cytokines aff ect, i.e. bone resorption or formation. Although these cytokines can infl uence both, the bone forming cells (osteoblasts) and the bone resorbing cells (osteoclasts), the majority of existing data is focused on the infl uence of immune cells on osteoclasts and thus on bone resorption. Nevertheless we have to take in account that pro-infl ammatory cytokines such as TNF-α and IL-17, released from activated T cells, can target osteoblasts as well.
The result of such infl uence is the increased production of pro-infl ammatory cytokines and RANKL in osteoblasts and thus the contribution of these cells to bone resorption (4) . Depending on their infl uence on osteoclast diff erentiation, activation or survival, the pro-infl ammatory cytokines can roughly be divided into osteoclastogenic, if they stimulate osteoclasts, or anti-osteoclastogenic, if they inhibit these unique bone-resorbing cells. Initially, the interplay between immune cells and osteoclasts has been observed in clinical settings of increased bone resorption following glucocorticoid therapy and in typical infl ammatory bone diseases, such as rheumatoid arthritis (RA) and periodontal disease. The cross-talk between immune and bone cells via cytokines, chemokines, growth factors, signaling molecules and transcription factors, has begun to be intensively studied with the onset of osteoimmunology. This terminus was fi rst mentioned in 2000, when Arron pointed out the importance of studying both, the skeletal and immune system, as an integrated entity (5) . The milestone for osteoimmunology however, dates far before that, already in 1972, when Horton et al. found a new soluble factor in the supernatant from cultures of stimulated human peripheral blood leukocytes that was capable to trigger in vitro bone resorption (6) . More than 20 years later, four diff erent groups of researchers independently characterized the receptor activator of nuclear factor κB ligand (RANKL), an essential molecule that controls osoteoclastogenesis and thus bone resorption. The fi rst two groups have found strong upregulation of RANKL in immune cells such as antigenstimulated T cells and in mature dendritic cells (7, 8) and the second two groups in bone marrow stromal cells (9,10). These fi ndings pinpointed the important role of RANKL within both, skeletal and immune system, leading to fi rst speculations that both systems might be functionally connected. However the main stimulus giving rise to osteoimmunology was the study of Takayanagi et al. in 2000, where they showed in vitro bone protecting action of IFN-γ (11). Every time our T cells are activated, they release RANKL, the osteoclast-stimulating molecule inducing bone resorption. Interestingly, IFN-γ binds to its receptor on osteoclasts, degrades RANKL signaling and thus inhibits the activation of osteoclasts and protects our bones from being resorbed. This cytokine is produced predominantly by NK and natural killer T (NKT) cells involved in the innate immune response, and by CD4 + Th1 and CD8 + cytotoxic T lymphocyte (CTL) eff ector T cells, once antigen-specifi c immunity develops (12).
As already mentioned the role of pro-infl ammatory cytokines has been most extensively studied in RA (13). With the advancement of osteoimmunology the involvement of these soluble factors in the pathogenesis of bone diseases that have traditionally not been considered as infl ammatory, such as osteoporosis (OP) and osteoarthritis (OA), has also been suggested (14,15).
The scope of this review is to summarize the current evidence on the infl uence of pro-infl ammatory cytokines on osteoclasts and thus on the process of bone resorption. In the fi rst part, the bone microenvironment, involving osteoclasts, osteoblasts and their connection to immune cells, will be addressed, while in the second part the osteoclastogenic, anti-osteoclastogenic and mixed (dual) eff ects of pro-infl ammatory cytokines will be reviewed. Finally, up to date evidence on the role of pro-infl ammatory cytokines in OP and OA will be summarized, with the aim to show that researching such complex bone disorders is almost impossible without considering skeletal and immune system in an integrated way.
Bone microenvironment
The interplay between bone and immune cells
Bone and immune cells are very similar meaning they have common progenitors in bone marrow, they require common receptors for cell signaling, and immune cells have shown the ability to diff erentiate into osteoclast as well.
Osteoclasts, macrophages and dendritic cells all derive from the same progenitors, i.e monocytemacrophage lineage (16). Besides RANKL and macrophage colony stimulating factor (M-CSF), which are essential for commitment of the common precursor to the osteoclast lineage and survival of generated osteoclasts, numerous cytokines are also able to infl uence osteoclast diff erentiation and/or function (17 . The determination of their exact role in bone microenvironment is even more diffi cult, as synergistic and antagonizing eff ects on osteoclasts of these cytokines have been observed (49-56). As already mentioned, the pro-infl ammatory cytokines can target osteoclasts directly or indirectly by modulating the RANK/RANKL/OPG system. The osteoclastogenic eff ect of these cytokines can be assessed by determining the expression of osteoclast-specifi c genes encoding RANK, calcitonin receptor, β 3 integrin, OSCAR, cathepsin K and TRAP, being involved in osteoclast diff erentiation, bone-resorbing activity and survival (23). The schematic representation of the infl uence of the pro-infl ammatory cytokines on osteoclast is shown in Figure 1 .
Cytokines with stimulating eff ects on osteoclasts (osteoclastogenic cytokines)
Mechanisms of action of osteoclastogenic pro-infl ammatory cytokines, the evidence on their opposite eff ects, and synergy or antagonism with other cytokines are summarized in Table 1 .
IL-1, existing in a form of IL-1α and IL-1β polypeptides, is produced by macrophages and is a potent stimulator of bone resorption, both in vitro and in vivo (57) (58) (59) (60) (61) . Similarly to IL-1, TNF is also represent- IL -interleukin; TNF-α -tumor necrosis factor α; RANKL -receptor activator of nuclear factor κB ligand; OPG -osteoprotegerin; Th17 -IL-17 producing T helper cells; NFATc1 -nuclear factor of activated T cells; OSCAR -osteoclast associated immunoreceptor; PGE 2 -prostaglandin E 2 ; NO -nitric oxide; OC -osteoclast. ed as a family of two related polypeptides α and β that are both potent stimulators of osteoclastogenesis (60, 62, 63) . TNF-α is produced by a variety of immune cells, primarily by macrophages, but also by NK cells, mast cells and T (Th1) and B lymphocytes. Anti-TNF-α antibody is used for the treatment of RA (12). IL-6, produced by T cells (Th2), dendritic cells and macrophages, is a pivotal cytokine in acute and chronic infl ammation. Interestingly, stromal cells and osteoblasts can also produce nanomolar quantities of IL-6 in response to TGF-β, IL-1 and TNF-α (64). The blocking of IL-6 signaling is eff ective in controlling RA symptoms (65) , as well as in vivo and in vitro blocking of osteoclast formation (66) . Interestingly, data on direct inhibition of osteoclast diff erentiation by IL-6 are also available (48). IL-11 is produced in bone marrow stromal cells and is required for normal bone remodeling (67) . In vitro studies have shown that it stimulates osteoclast formation and bone resorption (68) . Mice being defi cient in specifi c IL-11 receptor have increased trabecular bone mass due to decreased bone resorption (69) . IL-17 exists as a family of six distinctive cytokines (IL-17A -F) that are produced by a distinct lineage of T helper lymphocytes, the Th17 cells and are able to exert high osteoclastogenic activity (70) . In a synergy with TNF-α and IL-1, IL-17 has been causatively implied in the bone destruction observed in RA (71, 72) . IL-17A inhibition in an antigen-induced arthritis model, prevented joint and bone destruction and decreased the levels of RANKL, IL-1β, and TNF-α within pathologic lesions (73) . Recent study however showed, that the osteoclastogenic eff ect of IL-17A depends on its concentration, as only high concentrations of IL-17A were able to suppress osteoclastogenesis in vitro (74) . Like IL-17, IL-15 can also be produced by T lymphocytes, although its main sources are monocytes/macrophages and dendritic cells (75) and is involved in bone destruction in RA as well (76) . Mice defi cient in IL-15Rα, the specifi c IL-15 receptor subunit have increased bone mineral density (BMD) and decreased numbers of osteoclasts (77) . IL-8 belongs to a group of chemokines and is, unlike other osteoclastogenic cytokines that we have described up to this point, produced not only by T cells and macrophages but also by osteoclasts themselves. It has been shown to play an osteoclastogenic role in metastatic bone disease (78) . IL-32 is a relatively newly described cytokine showing typical properties of a pro-infl ammatory mediator, as it stimulates TNF-α, IL-1β and IL-8 production. It exerts complex osteoclastogenic eff ects, such as promoting osteoclast differentiation but not maturation of osteoclasts (79) .
Cytokines with inhibiting eff ects on osteoclasts (anti-osteoclastogenic cytokines)
The mechanisms of action of anti-osteoclastogenic pro-infl ammatory cytokines, the evidence on their functional eff ects, as well as synergy or antagonism with other cytokines, are summarized in Table 2 .
IFN-γ, a type II interferon, which is produced by Th1 lymphocytes and NK cells, is a potent inducer of antigen presentation and therefore of T cell activation. As previously mentioned, the discovery of IFN-γ anti-osteoclastogenic eff ect in vitro has initiated development of osteoimmunology (11). In vivo eff ects of IFN-γ on bone tissue are more difficult to categorize and often indicate its opposite, osteoclastogenic eff ect as well (43,80,81). It seems that IFN-γ functions as an anti-osteoclastogenic cytokine in physiological conditions of bone turnover as proven by lower BMD in nude and IFN-γ receptor defi cient mice (43,81). However, in pathological bone turnover such as in postmenopausal OP, infl ammation or bacterial infection, the net effect of IFN-γ is biased towards bone resorption via antigen driven T cell activation and RANKL production (43). In rats, intraperitoneal IFN-γ injections induced osteopenia (82), while in humans this cytokine has been reported to be effi cacious in the treatment of osteopetrosis as it restores bone resorption (83).
Comparing to IFN-γ, there are fewer studies published on the eff ects of type I interferons, IFN-α and IFN-β. However, the existing data on the antiosteoclastogenic activity of IFN-β are quite uniform (84). Namely, mice that are defi cient in IFN-β exhibit severe osteopenia accompanied by enhanced osteoclastogenesis (85). In order to suppress the anti-osteoclastogenic eff ects of IFN-β, osteoclast precursors have been shown to upregulate the expression of the suppressors of cytokines signaling (SOCS) (86). Recently, the upregulation of IFN-β expression has been suggested as a basic molecular mechanism needed for the effi cacy of vitamin D (1α,25(OH) 2 D 3 ) used to treat human bone diseases (87). In animal models of RA, the application of IFN-β resulted in signifi cantly reduced cartilage and bone destruction accompanied by downregulated expression of TNF-α and IL-6, as well as increased expression of IL-10 (88).
There are even much more limited data on IFN-α, showing its anti-osteoclastogenic eff ects in vitro (89). In vivo no eff ect of IFN-α on bone turnover could be detected in rats (90), however in mice models of systemic lupus erythematosus it was shown to decrease bone resorption (91). Children receiving IFN-α therapy due to chronic hepatitis B have been shown to have higher femoral BMD (92).
IL-4 and IL-13 are anti-osteoclastogenic cytokines, moreover they have shown infl uence on osteoblast as well (93,94). Transgenic mice overexpressing IL-4 develop an osteoporotic phenotype (95) that may result from both, the inhibition of osteoclast formation and their activity (96,97), as well as the inhibition of osteoblasts and bone formation (94). Both interleukins have also been shown to inhibit IL-1 stimulated bone resorption by decreasing the activity of cyclooxygenase-2 (COX-2) and thereby the production of prostaglandins (98). Additionally, IL-4 has the ability to inhibit osteoclastogenesis being physiologically stimulated by RANKL or pathologically by TNF-α (99).
IL-10 is produced by monocytes, T cells and B cells (100) and inhibits not only osteoclastogenesis (101-105) but also osteoblastogenesis and the onset of mineralization (106) .
Besides IL-17 and IL-23, IL-18 has been also found to be increased in infl ammation sites in RA (56). Al- (194) ↓ RANKL-induced osteoclasts formation (195) synergy with IL-12 (125) IFN -interferon; IL -interleukin; RANK -receptor activator of nuclear factor κB; OPG -osteoprotegerin; PTH -parathyroid hormone; TNF-α -tumor necrosis factor α; NO -nitric oxide; CXCL11; -chemokine ligand 11; TRAP -tartrate-resistant acid phosphatase; NFATc1 -nuclear factor of activated T cells; TRAF6 -TNF receptor associated factor 6; STAT6 -signal transducer and activator of transcription 6; GM-CSF -granulocyte macrophage colony stimulating factor; TREM2 -triggering receptor expressed by myeloid cells 2. (111) . IL-33 is another member of the IL-1 superfamily, and recent data suggest that similarly to IL-18, it has anti-osteoclastogenic eff ects (112, 113) .
Cytokines with dual (opposite) eff ects on osteoclasts
The mechanisms of action of pro-infl ammatory cytokines with mixed, osteoclastogenic and antiosteoclastogenic eff ects are summarized in Table 3 .
IL-7 is produced by stromal cells in red bone marrow and thymus, keratinocytes, follicular dendritic cells and other non-hematopoietic cells. The production of IL-7 was enhanced in ovariectomized (OVX) mice where it stimulated osteoclastogenesis (114) . Another study found that in IL-7 defi cient mice, as compared to wild-type animals, the numbers of osteoclasts increased and the trabecular bone volume decreased; however both types of mice displayed similar bone loss following OVX (115) . Addition of IL-7 to murine bone marrow cells cultured in the presence of M-CSF and RANKL, inhibited osteoclast formation as well (116) . Recently, mice overexpressing human IL-7 in their osteoblast lineage were found to have increased trabecular bone volume in vivo and decreased osteoclast formation in vitro (117) . In thymectomized women the levels of IL-7 and RANKL were increased compared to controls, however their RANKL/OPG ratios and indices of bone metabolism were not aff ected (118) . In humans, IL-7 has shown its osteoclastogenic nature in psoriatic arthritis (119) and in solid tumors bearing patients (120), while in those suffering from RA it was suggested to contribute to the perpetuation of Th1 and TNF-α mediated proinfl ammatory immune responses (121) .
IL-12 is another controversial cytokine in terms of its anti-osteoclastogenic/ osteoclastogenic eff ects (122). It is produced by myeloid cells, i.e. dendritic cells and macrophages and induces diff erentiation and activation of Th1 lymphocytes and their subsequent production of IFN-γ and GM-CSF (123,124). There are confl icting results on the involvement of IFN-γ in IL-12 mediated osteoclastogenesis inhibition as well (50,125).
IL-23 is produced by dendritic cells and macrophages. It plays a role in bone destruction in RA, as shown in mice models of RA, with animals being defi cient for either IL-17 or IL-23 (70, 126) , and in rat models of collagen-induced arthritis, where an- 
synergy with IL-18 in blocking osteoclastogenesis (128) IFN -interferon; IL -interleukin; RANKL -receptor activator of nuclear factor κB ligand; TNF-α -tumor necrosis factor α; Th1 -type I helper T cells; Th17 -Th subpopulation expressing IL-17.
TABLE 3.
Cytokines with osteoclastogenic and anti-osteoclastogenic properties.
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imals were treated with anti-IL-23 antibodies (127) . However, in non-pathological conditions IL-23 functions in an opposite, anti-osteoclastogenic way (128) .
Transforming growth factor β
TGF-β, an ubiquitous growth factor, is not a probut an anti-infl ammatory cytokine, playing an important and complex role in bone remodelling by infl uencing bone resorption, formation and the production of certain pro-infl ammatory cytokines (47,49). It is produced by many diff erent cells, including macrophages and exists in at least three isoforms, TGF-β1, TGF-β2 and TGF-β3. Recently, the role of TGF-ß1 in coupling bone formation and resorption has been suggested (129) . Its eff ects on osteoclasts cultured in vitro greatly depend on numerous factors, such as: diff erentiation stage of the starting cell population, cell density, the presence or absence of serum in the cell culture medium, concentration of added TGF-ß1, and whether its eff ect was studied on isolated cells or in co-cultures. In vivo the presence of other cytokines such as IL-1, IL-6, TNF-α, IFN-γ, prostaglandin E 2 (PGE 2 ) etc. and environment as such determine the exact outcome of TGF-ß1 activity (47,51).
The pro-infl ammatory cytokines and bone diseases
In many pathological conditions, activated immune cells such as T lymphocytes, macrophages and dendritic cells produce a variety of pro-infl ammatory cytokines which in turn modulate osteoclast activity and bone resorption as already described above. In continuation we will provide actual data on the roles of certain pro-infl ammatory cytokines in two common bone diseases, OP and OA.
The role of pro-infl ammatory cytokines in osteoporosis
Osteoporosis has been traditionally considered an endocrine disease resulting mainly from the estrogens decline after menopause. This change aff ects bone remodeling, leading to impaired microarchitecture of bone tissue and consequently to higher risk of fractures. Since solely the endocrine point of view does not fully explain the pathogenesis of OP, the osteoimmunological approach suggests that activated T lymphocytes can contribute to menopausal changes in bone remodeling by producing pro-infl ammatory cytokines such as TNF-α, IL-1, IL-6, IL-7 and IFN-γ (130, 131) . This statement has caused a paradigm shift in the pathogenesis of OP, which can now be also classifi ed as an infl ammatory disease (4, 15, 132) . The eff ects of pro-infl ammatory cytokines have been initially studied in OVX mice which represent an experimental model of postmenopausal OP. Nude mice that are deficient in T cells were found to be resistant to bone loss following acute estrogen decline, artifi cially caused by OVX. It has been proposed that this was due to the lack of CD4 + subpopulation of T lymphocytes (130) . Another mechanism of bone loss due to estrogen decline is the enhanced TNF-α production by activated T cells (133, 134) . Mice deficient in IL-1 receptor (135), TNF-α (133,136) or IL-6 (68) did not lose bone mass following OVX, while no diff erence in bone loss could be found between IL-7 defi cient mice and the wild type animals (115). However, there are also studies showing the opposite eff ects. Namely, no infl uence on trabecular bone loss has been observed in mice lacking functional T lymphocytes after OVX (137) , and additionally nude mice can develop OP as well (138) . Studies in humans have shown higher T cell activity and increased levels of IL-1, TNF-α and IL-6 in postmenopausal osteoporotic women (130, (139) (140) (141) (142) (143) . Higher expression of RANKL/OPG and M-CSF in patients with fragility fracture has also been reported (144) . Furthermore, increased serum levels of IL-6 were proved to account for up to 34% of the total variance of BMD change within the fi rst few years after the onset of menopause (145) . In Figure  2 , the connections of the pro-infl ammatory cytokines with OP phenotype in patients with low-energy femoral neck fractures are presented according to results of our recently published study (146) . In this study we found higher expression of genes encoding for IL-1α, IL-6, RANKL and RANK in osteoporotic bone tissue. Additionally, we have found two genetic variants in IL-1α gene showing possible infl uence on osteoporotic phenotype, such as 
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Hip BMD and TNF-α (-) (147) . It has been suggested that activated T cells could contribute to enhanced osteoclastogenesis in two ways, fi rst by increasing the production of bone resorbing cytokines, especially TNF-α and RANKL, and secondly, by increasing the numbers of osteoclast precursors (139, 148) . Bone cells isolated from untreated postmenopausal women showed higher mRNA expression for IL-1, TNF and IL-6 in comparison to those taken from women on estrogen replacement therapy (149) . A blockade of both, TNF and IL-1 reduced bone resorption in postmenopausal osteoporotic women (150) . Interestingly, Canadian multicentre osteoporosis study showed that treatment with COX-2 inhibitors was associated with higher BMD in postmenopausal women not taking estrogen (151) . When looking at the extent of IFN-γ production, no diff erences between postmenopausal osteoporotic and healthy women were found (152) . As already mentioned in case of IFN-γ, diff erences exist in eff ects of pro-infl ammatory cytokines on osteoclasts depending on whether the bone is being remodelled under physiological or pathological conditions. In pathological conditions such as infl ammation, infection and estrogen defi ciency, Gao et al. have shown that the net balance between osteoclastogenic and anti-osteoclastogenic eff ect of IFN-γ is shifted towards osteoclastogenesis and bone resorption (43). This is due to predominant indirect eff ect of IFN-γ that presents enhanced antigen presentation by IFN-γ to T cells leading to T cells' activation, proliferation and production of osteoclastogenic cytokines, such as RANKL and TNF-α. In vivo, this indirect (via RANKL) osteoclastogenic activity overcomes the direct suppressive action of IFN-γ on osteoclast precursors, leading to a net bone loss. Similarly, IL-6 does not seem to play an osteoclastogenic role under physiological conditions such as the estrogen-replete state (131) .
Bone Turnover Markers
Rodent models were used to show that TGF-β1 and TGF-β2 prevent bone loss following OVX (153) and that estrogen upregulates the expression of TGF-β (154) . There is also evidence on the involvement of TGF-β into a mechanism by which estrogen defi ciency upregulates the production of IFN-γ (155, 156) . In humans, long-term in vivo estrogen treatment has been shown to increase serum levels of TGF-β1 and TGF-β2 (157) .
The role of pro-infl ammatory cytokines in osteoarthritis
The role of pro-infl ammatory cytokines such as IL-17, IL-1 and TNF-α in bone loss has been most intensively elucidated in RA and periodontal disease. In contrast to RA, OA has long been considered an age-related degenerative disease of cartilage with accompanying pathological changes in subchondral bone. Since the concept of synovial infl ammation contributing to OA was suggested, numerous studies have shown that the infl amed synovium and activated synovial macrophages importantly promote the osteoarthritic pathology (14,158,159). These results provided the missing infl ammatory component to the pathology of this disease. Unlike in OP, where the infl uence of pro-infl ammatory cytokines has been focused on bone cells, the most intensively studied targets of these soluble factors in OA are synovial cells and chondrocytes. Synovial biopsy specimens taken from patients with early OA or RA are similar in cell morphology and cytokine spectra, although the percentage of macrophages, T and B lymphocytes, as well as the levels of TNF-α and IL-1, are generally lower in OA (160) . TNF-α and IL-1 have been suggested as key players in pathogenesis of OA. Namely, they have been shown to promote their own production, induce synovial cells and chondrocytes to produce other pro-infl ammatory cytokines such as IL-6 and IL-8, as well as to stimulate protease and prostaglandin production (158, 161, 162) . Animal models and human studies of OA have shown decreased cartilage damage following anti-IL-1 antibody therapy or gene transfer of IL-1Ra, the IL-1 receptor antagonist (163, 164) . In mice with OA, being defi cient in IL-1 the pathology of OA was reduced (162, 165) . However, another study in IL-1 defi cient mice found the opposite results (166) , indicating a more complex role of IL-1 in OA. In our opinion this disrepancy could be due to diff erent models of OA in animals, whether IL-1 or just IL-1β was studied or similarly to IFN-γ, IL-1 could play dual role depending on the presence of other cytokines. Interestingly, IL-4, IL-10 and IL-13 that are classifi ed as anti-
Osteoimmunology and pro-infl ammatory cytokines osteoclastogenic cytokines according to their infl uence on bone, have fully proven their anti-infl ammatory role in OA. They were increased in synovial fl uid of OA patients and were shown to inhibit a number of pro-infl ammatory cytokines, such as IL-1β, TNF-α, PGE 2 , etc. (161).
Synovial macrophages play an important role in perpetuating the production of pro-infl ammatory cytokines and mediating osteophyte formation and fi brosis in subchondral osteoarthritic bone (167) . The latter two processes may also be under control of TGF-β (168) . Namely, the inhibition of TGF-β markedly reduced both, fi brosis and osteophyte formation. The impaired TGF-β signaling then leads to chondrocyte hypertrophy and results in osteoarthritic pathology of cartilage as well (168, 169) .
Data on the infl uence of pro-infl ammatory cytokines on osteoarthritic bone are scarce. A recent study pinpointed the increased gene expression of TGF-β (144). Our own data have shown higher expression of TGF-β1 receptor and the anti-osteoclastogenic cytokine IFN-γ in bone tissue samples of osteoarthritic patients, and connections of the pro-infl ammatory cytokines with BMD, serum levels of bone turnover markers and osteoclast-specifi c genes as shown in Figure 2 (146) . Another study in primary hip osteoarthritic patients showed positive correlations between IL-8 and bone resorption marker CTX, C terminal telopeptide of collagen type I in both, serum and synovium (170) . However most of the published data indicate that in human OA, RANKL, released from activated T cells and synoviocytes, is the principal mediator of bone destruction. Additional proof for that is the fact that RANKL inhibition does not diminish infl ammation but eff ectively prevents bone loss at the site of infl ammation (35). Also, in randomized controlled clinical trials no eff ect in preventing bone loss in patients with RA following IFN-γ treatment could be found (171) .
Conclusion
Thanks to recent advances in osteoimmunology, remarkable progress has been made in elucidating dynamic cross-talk between bone and immune cells that takes place in a complex bone microenvironment. Osteoimmunology has postulated a new approach to studying bone diseases such as OP and OA that were traditionally not considered to be infl ammatory. Data reviewed in this paper provide an insight into the infl uence of pro-infl ammatory cytokines on osteoclasts and thus on the bone resorption. They clearly show that T cell-derived cytokines can exert diff erent eff ects on osteoclasts very much depending on whether a study was performed in vitro or in vivo. A huge step forward to elucidation of interactions between immune and skeletal system has been made by using animal models such as OVX mice and rodent models of OA. However, further studies in humans will be critical for clearly understanding the roles of pro-infl ammatory cytokines in bone loss with the aim of raising novel therapeutic strategies for these kinds of patients. 
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